Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19.
Rae MaedaNatsumi SekiYoshifumi UwaminoMasatoshi WakuiYu NakagamaYasutoshi KidoMiwa SasaiShu TairaNaoya ToriuMasahiro YamamotoYoshiharu MatsuuraJun UchiyamaGenki YamaguchiMakoto HirakawaYun-Gi KimMasayo MishimaMotoko YanagitaMakoto SuematsuYuki SugiuraPublished in: Nature communications (2023)
Effective early-stage markers for predicting which patients are at risk of developing SARS-CoV-2 infection have not been fully investigated. Here, we performed comprehensive serum metabolome analysis of a total of 83 patients from two cohorts to determine that the acceleration of amino acid catabolism within 5 days from disease onset correlated with future disease severity. Increased levels of de-aminated amino acid catabolites involved in the de novo nucleotide synthesis pathway were identified as early prognostic markers that correlated with the initial viral load. We further employed mice models of SARS-CoV2-MA10 and influenza infection to demonstrate that such de-amination of amino acids and de novo synthesis of nucleotides were associated with the abnormal proliferation of airway and vascular tissue cells in the lungs during the early stages of infection. Consequently, it can be concluded that lung parenchymal tissue remodeling in the early stages of respiratory viral infections induces systemic metabolic remodeling and that the associated key amino acid catabolites are valid predictors for excessive inflammatory response in later disease stages.
Keyphrases
- amino acid
- end stage renal disease
- sars cov
- inflammatory response
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- type diabetes
- induced apoptosis
- intensive care unit
- oxidative stress
- radiation therapy
- physical activity
- metabolic syndrome
- cell proliferation
- squamous cell carcinoma
- body mass index
- insulin resistance
- lipopolysaccharide induced
- respiratory syndrome coronavirus
- lps induced
- patient reported outcomes
- lymph node
- mass spectrometry
- neoadjuvant chemotherapy